NeoGenomics (NEO)

• Market cap: $2.21B
• 1 day: -4.55%
• 5 days: -3.64%
• 1 month: 15.14%
• 3 months: 6.05%
• 6 months: 27.81%
• Year to date: 7.77%
• 1 year: -6.98%
• 5 years: -34.06%
• 10 years: 308.31%
• Sector: Industrials
• Industry: Testing Laboratories

About: NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Employees: 2,100

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

449% more call options, than puts

Call options by funds: $12.3M | Put options by funds: $2.24M

31% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 29

4% more funds holding

Funds holding: 257 [Q2] → 266 (+9) [Q3]

2% more capital invested

Capital invested by funds: $1.77B [Q2] → $1.8B (+$37.5M) [Q3]

4.17% less ownership

Funds ownership: 99.79% [Q2] → 95.62% (-4.17%) [Q3]

23% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 92

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18 5% upside
• Avg. target: $18.67 9% upside
• High target: $19 11% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson 66% 1-year accuracy 61 / 92 met price target	11% upside $19	Buy Reiterated	6 Nov 2024
Needham Mike Matson 66% 1-year accuracy 61 / 92 met price target	11% upside $19	Buy Reiterated	25 Sept 2024
Benchmark Bruce Jackson 41% 1-year accuracy 21 / 51 met price target	5% upside $18	Buy Reiterated	24 Sept 2024